Loading the section
The price of Viking Therapeutics, Inc. (VKTX) on October 9, 2026 is 28.51 USD, +2.81% on the day. Over 52 weeks the stock traded between 25.77 USD and 43.15 USD; the price now sits 16% of the way up that range. Over the past year the price changed by -11.92%. Market capitalization is 3.18 billion USD, rank 53 among 374 stocks of the same industry with a known capitalization.
Closing prices for 09 October 2026
Next earnings report: 28 October 2026 · Earnings calendar
Viking Therapeutics, Inc. trades on Nasdaq under the ticker VKTX. The company belongs to the Health care sector. The trading history on this page starts on 22 August 2016.
Over the past 52 weeks VKTX has traded between 25.77 $ and 43.15 $. As of 09 October 2026 the price stood 15.77 % of the way from the 52-week low to the high.
Over one year VKTX shares fell 11.92 %; over six months they fell 16.78 %. Volatility over 90 days is 76.26 %. Dividends are not included: this is price change only, as of 09 October 2026.
The company reported a loss over the last four quarters, so a price-to-earnings ratio is not calculated. Price to book is 6.3, above the sector median of 2.4. Calculated from reports for the period ending 31 March 2026.
| Date | Open | High | Low | Close | Volume, shares |
|---|---|---|---|---|---|
| 09 October 2026 | 27.85 | 28.86 | 27.58 | 28.51 | 4M |
| 08 October 2026 | 28.37 | 28.49 | 27.05 | 27.73 | 9M |
| 07 October 2026 | 28.39 | 29.06 | 28.12 | 28.54 | 5M |
| 06 October 2026 | 29.49 | 29.72 |
The series is stated in the current share scale after splits; dividends are not included in the price
Based on the last 12 months of reports, through 31 March 2026
The sector median covers every company in the sector on the US market, loss-making ones included.
Viking Therapeutics, Inc. (VKTX) is a public company in the healthcare sector. Its common stock trade on NASDAQ.
Over the trailing twelve months as reported to 2025-12-31, revenue was 0 $, net income was -359.6m $. Incorporated in US.
This summary is compiled automatically from SEC filings and exchange data.
Address:9920 PACIFIC HEIGHTS BLVD, SUITE 350, SAN DIEGO, CA, 92121, US
Viking Therapeutics, Inc. reported revenue of 0 $ and a net loss of 472M $ over the last four quarters. Earnings per share are −4.15 $. Market capitalisation is 3.2B $.
VKTX has a return on equity of −94.11 %, below the sector median of −41.68 %. Return on assets is −77.66 %, below the sector median of −32.11 %.
| 1.2B |
| PFEPfizer, Inc. | 28.18 | +1.28 % | 929M |
| ABTAbbott Laboratories | 99.60 | +1.13 % | 921M |
| BMYBristol-Myers Squibb Company | 59.12 | −0.77 % | 714M |
| REGNRegeneron Pharmaceuticals, Inc. | 746.54 | +0.94 % | 555M |
| 28.17 |
| 28.38 |
| 7M |
| 05 October 2026 | 30.14 | 30.18 | 28.71 | 29.28 | 6M |
| 02 October 2026 | 30.85 | 31.09 | 29.90 | 29.94 | 6M |
| 01 October 2026 | 31.92 | 32.48 | 30.43 | 30.51 | 7M |
| 30 September 2026 | 31.86 | 33.29 | 31.20 | 32.60 | 7M |
| 29 September 2026 | 33.11 | 33.65 | 31.42 | 31.81 | 8M |
| 28 September 2026 | 35.00 | 35.19 | 32.91 | 33.03 | 9M |
| 25 September 2026 | 37.80 | 39.05 | 35.10 | 35.56 | 14M |
| 24 September 2026 | 36.03 | 37.22 | 35.11 | 36.75 | 29M |
| 23 September 2026 | 41.76 | 43.10 | 37.71 | 41.65 | 16M |
| 22 September 2026 | 37.00 | 41.73 | 36.34 | 40.85 | 41M |
| 21 September 2026 | 29.57 | 30.70 | 28.41 | 30.11 | 5M |
| 18 September 2026 | 29.57 | 29.68 | 28.40 | 28.99 | 3M |
| 17 September 2026 | 30.24 | 30.54 | 29.26 | 29.36 | 2M |
| 16 September 2026 | 30.02 | 30.77 | 28.80 | 29.52 | 3M |
| 15 September 2026 | 31.21 | 31.25 | 29.70 | 29.95 | 3M |
| 14 September 2026 | 31.70 | 32.43 | 31.39 | 31.53 | 2M |